Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Prenetics Global Limited Class A Ordinary Share (PRE)

Prenetics Global Limited Class A Ordinary Share (PRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,486
  • Shares Outstanding, K 9,137
  • Annual Sales, $ 21,740 K
  • Annual Income, $ -62,720 K
  • 60-Month Beta -0.16
  • Price/Sales 1.94
  • Price/Cash Flow N/A
  • Price/Book 0.20
Trade PRE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +666,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.10 +10.34%
on 08/29/24
6.97 -35.08%
on 08/19/24
-0.95 (-17.43%)
since 08/16/24
3-Month
4.10 +10.34%
on 08/29/24
6.99 -35.26%
on 07/12/24
-1.42 (-23.95%)
since 06/18/24
52-Week
2.85 +58.77%
on 04/19/24
7.84 -42.27%
on 04/24/24
-2.97 (-39.67%)
since 09/18/23

Most Recent Stories

More News
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

PRE : 4.53 (-2.69%)
Why Prenetics Global Stock Is Skyrocketing Today

The company announced a key FDA clearance.

PRE : 4.53 (-2.69%)
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics

HONG KONG, Dec 16, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT,...

PRE : 4.53 (-2.69%)
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON AND HONG KONG, Nov 30, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its...

PRE : 4.53 (-2.69%)
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON AND HONG KONG, Nov 10, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited...

HSBC : 43.91 (+0.53%)
PRE : 4.53 (-2.69%)
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

LONDON AND HONG KONG, Sep 9, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited...

PRE : 4.53 (-2.69%)
Younger Colorectal Cancer Population Highlights the Importance of Early Screening, Highly Sensitive Test Product Prenetics has Launched the Market

HONG KONG, Sep 2, 2022 - (ACN Newswire) - Colorectal cancer (CRC) has become one of the main cancers threatening the health of human beings. In the United States and China, CRC has ranked among the top...

PRE : 4.53 (-2.69%)
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%

HANGZHOU, Aug 19, 2022 - (ACN Newswire) - New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022...

PRE : 4.53 (-2.69%)
Citi Initiates Coverage on Prenetics Global with "Buy" Rating, Target Price at USD8.10

HONG KONG, Jul 13, 2022 - (ACN Newswire) - It is reported that Citi initiated coverage on Prenetics Global (PRE.US) with "Buy" rating. Target price is at USD8.10, apply 3x P/S 2023E, at parity with the...

PRE : 4.53 (-2.69%)
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker “PRE.”

LONDON and HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic...

PRE : 4.53 (-2.69%)

Business Summary

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof....

See More

Key Turning Points

3rd Resistance Point 4.95
2nd Resistance Point 4.80
1st Resistance Point 4.66
Last Price 4.53
1st Support Level 4.38
2nd Support Level 4.23
3rd Support Level 4.09

See More

52-Week High 7.84
Fibonacci 61.8% 5.93
Fibonacci 50% 5.34
Fibonacci 38.2% 4.76
Last Price 4.53
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar